[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vera Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":5},"100591638","phase-2-atacicept-in-multiple-glomerular-diseases-100591638",false,"NCT06983028","Atacicept in Multiple Glomerular Diseases","A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)","Inclusion Criteria:\n\n* Weight of at least 40 kg\n* On a stable prescribed standard of care (SoC) treatment regimen according to local guidelines and the specific requirements for each disease\n* Systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤90 mmHg at Screening.\n\nDiagnosis of IgAN, IgAVN, pMN, MCD, FSGS, or primary nephrotic syndrome\n\nFor patients enrolling in IgAN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy proven IgAN, IgAVN, or recurrent IgAN in kidney transplant\n* UPCR ≥ 0.5 g\u002Fg or UPE ≥ 0.5 g\u002Fday on 24h urine\n* eGFR≥ 20 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pediatric IgAN Cohorts (eligibility varies by cohort):\n\n* Age ≥ 2 years and \\\u003C 18 years\n* Biopsy proven IgAN or IgAVN\n* On stable prescribed regimen of RAASi (or SoC) for at least 8 weeks\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* eGFR≥ 30 mL\u002Fmin\u002F1.73m2\n\nFor patients enrolling in pMN cohorts (eligibility varies by cohort):\n\n* Age ≥ 18 years\n* Biopsy-proven pMN\n* Anti PLA2R antibodies ≥ 25 RU\u002FmL\n* UPCR ≥ 1.5 g\u002Fg or UPE ≥ 1.5 g\u002Fd on 24h urine\n* At low risk for spontaneous remission (based on severity or duration of disease)\n\nFor patients enrolling in Nephrotic Syndrome cohorts (MCD, FSGS, or pediatric idiopathic nephrotic syndrome):\n\n* Age ≥ 10 years\n* eGFR ≥30 mL\u002Fmin\u002F1.73m2\n* Adults with biopsy diagnosis of primary MCD or FSGS (adults) or children with challenging clinical course with steroids (frequenlty relapsing, steroid-dependent, or steroid-resistant)\n* UPCR ≥ 1.0 g\u002Fg or UPE ≥ 1.0 g\u002Fd on 24h urine\n* Evidence of anti-nephrin antibodies\n\nKey Exclusion Criteria:\n\n* Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR) within 12 weeks prior to and at Screening)\n* Active viral or bacterial infections\n* Existing conditions or clinically significant laboratory abnormalities that may interfere with participation in this study\n* Administration of live and live-attenuated vaccinations within 30 days prior to enrollment\n* Immunosuppressant medications within 4 weeks prior to dosing with atacicept (except transplant maintenance immunosuppression).\n* Known hypersensitivity to atacicept or any component of the formulated atacicept\n* Additional criteria apply to each cohort\u002Fdisease.","ALL","2 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.",[26,27,28,29,30],"pMN","IgAN","Nephrotic Syndrome","MCD","FSGS",[32,33,34,35,36,37,28,38,39,40,41,42,43,44,45,46,47],"IGA Glomerulonephritis","IGA Nephropathy","Iga Nephropathy 1","Immunoglobulin A Nephropathy Nephritis","IGA Type Nephropathy, IGA","Primary Membranous Nephropathy","Immunoglobulin A (IgA)","Immunoglobulin A vasculitis with nephritis (IgAVN)","Anti-PLA2R associated membranous nephropathy (PLA2R-MN)","Idiopathic\u002Fprimary nephrotic syndrome (MCD\u002FFSGS)","Glomerulonephritis","Nephritis","Autoimmune Diseases","Immune System Diseases","Kidney Diseases","Glomerulonephritis, IGA","RECRUITING","2026-06-23",{"date":51,"type":52},"2026-06-26","ACTUAL",{"date":54,"type":52},"2025-07-07",{"date":56,"type":20},"2027-11",{"name":58,"class":59},"Vera Therapeutics, Inc.","INDUSTRY",""]